Skip to main content
World Today News
  • Home
  • News
  • World
  • Sport
  • Entertainment
  • Business
  • Health
  • Technology
Menu
  • Home
  • News
  • World
  • Sport
  • Entertainment
  • Business
  • Health
  • Technology
Stopping GLP-1 Drugs Doubles Nonfatal MI, Stroke, Death Risk in T2D

Stopping GLP-1 Drugs Doubles Nonfatal MI, Stroke, Death Risk in T2D

November 19, 2026 Health Desk Health

“These medications actually have a very clear cardiovascular benefit, which is known, and if you stop them, you don’t get that cardiovascular benefit,” cardiologist and epidemiologist Christopher Labos of McGill University told Global News this week.

People with type 2 diabetes who stop taking GLP-1 receptor agonists faced roughly double the combined risk of heart attack, stroke, or death from any cause compared with those who stayed on treatment, according to a retrospective cohort study published on November 9 in The Lancet Regional Health – Europe.

Key Clinical Takeaways:

  • Discontinuing GLP-1 therapy was linked to about twice the rate of nonfatal heart attack, nonfatal stroke, or death in people with type 2 diabetes and no prior cardiovascular disease.
  • All-cause death rates were more than four times higher after stopping, a gap the authors say stopping alone is unlikely to explain.
  • The study is observational: researchers did not know why patients quit, so reverse causation remains possible.

A 20-year record from 301 Italian clinics

The analysis drew on electronic medical records from 301 diabetes clinics across the Italian Association of Clinical Diabetologists database, collected between 2004 and 2024, Medscape reported. Of 80,302 patients with type 2 diabetes and no established cardiovascular disease who started a GLP-1 receptor agonist, 48,615 discontinued treatment and 31,687 persisted. Discontinuation meant no prescription at two or more consecutive visits.

After propensity-score matching, the researchers compared two balanced cohorts of 28,713 patients each, with a mean age of about 64.6 years and women making up just under 40 percent of each group, Medscape reported. Persistent users averaged nearly three years on the drugs; those who stopped averaged just over one year of treatment, The Independent reported.

Stopping GLP-1 Drugs Doubles Nonfatal MI, Stroke, Death Risk in T2D
Photo: The Independent

The primary endpoint — nonfatal myocardial infarction, nonfatal stroke, or death from any cause — occurred at 3.94 events per 100 person-years among those who stopped, against 1.96 among persistent users. The incidence rate ratio was 2.01, and the hazard ratio was 2.03.

Endpoint Persistent users After discontinuation Hazard ratio
Heart attack, stroke, or death 1.96 per 100 person-years 3.94 per 100 person-years 2.03
Death from any cause 0.48 per 100 person-years 2.23 per 100 person-years 4.81

Death from any cause showed the widest gap: 0.48 per 100 person-years among persistent users versus 2.23 after discontinuation, Medscape reported. The authors themselves cautioned that stopping alone is unlikely to explain a mortality difference that large, Medical Xpress reported.

Obesity sharpened the association. The hazard ratio for the primary endpoint was 2.27 in patients with a body mass index of 30 or higher, compared with 1.61 below that threshold, per Medscape.

What the risk factors did not show

The puzzle driving the research is what actually raises the risk. Within the discontinuation group, risk factor trends differed only slightly between patients who later had an event and those who did not, Medscape reported.

News-Medical reported that only modest weight regain followed cessation, with no deterioration in glycemic control — raising the possibility that GLP-1 receptor agonists carry cardiovascular benefits beyond their effects on conventional risk factors, though the authors called that speculative.

Instagram

The study was funded in part by the Italian Ministry of Health through IRCCS MultiMedica, and several authors disclosed advisory, consulting, or research ties with multiple companies, Medscape reported. The lead author is Antonio Ceriello of IRCCS MultiMedica in Milan.

Observational design cannot prove causation

Because the design is observational, unmeasured confounding and reverse causation could not be ruled out. The researchers had no data on why patients stopped — side effects, cost, frailty, or illness such as cancer could all play a role — nor on socioeconomic factors or cause of death, and heart-failure hospitalizations were inconsistently captured, Medscape reported.

The BMJ’s analysis, cited by Global News, made the same caution: the data cannot show whether discontinuing the drugs caused the added risk or whether patients who stopped were already in poorer health.

The findings also may not extend to people taking GLP-1s for obesity without diabetes, or to tirzepatide, which was not evaluated, Medscape reported.

Stopping GLP-1 Drugs Doubles Nonfatal MI, Stroke, Death Risk in T2D
Photo: News-Medical

The experts’ split verdict

Dr. Faye Riley, who leads research communications at Diabetes UK, told The Independent that further studies are required to clarify what happens when patients come off these drugs, as well as the advantages and drawbacks of taking them over extended periods.

Riley added that for people prescribed the drugs, they should be used alongside heart-healthy behaviors — a varied, balanced diet with plenty of protein and fibre, and regular physical activity including strength exercises.

“If the interpretation you draw from this is that you shouldn't just be starting and stopping these medications on a whim, I think that's the correct interpretation,” cardiologist and epidemiologist Christopher Labos of McGill University told Global News.

Writing in Medscape, the study team reported that at four years of follow-up, patients with type 2 diabetes and no cardiovascular disease who began GLP-1 treatment but then discontinued it faced a greater likelihood of the combined outcome of heart attack, stroke, or death from any cause than counterparts who remained on the medication.

Glp discontinuation linked to higher h
Photo: UA.NEWS

Authors call for prospective trials on discontinuation risk

The authors describe the results as hypothesis-generating and are calling for prospective studies designed specifically to test whether stopping GLP-1 therapy directly raises cardiovascular risk, News-Medical reported. Up to half of people on these drugs stop within the first year, Medical Xpress reported, so the discontinuation question touches a large share of the population now prescribed them.

In the meantime, the practical takeaway for patients weighing a stop — whether because of side effects, cost, or supply — is to make that decision with their care team rather than alone; endocrinologists, diabetes educators, and pharmacists can weigh alternatives such as dose adjustment, switching agents, or backup cardiometabolic therapy. As Labos put it, these medications should not be started and stopped on a whim.

The comment from Labos came from one of Canada’s oldest institutions of medical research. McGill University, an English-language public research university in Montreal, Quebec, was founded in 1821 by royal charter and takes its name from James McGill, a Scottish merchant whose bequest in 1813 established the college. Its enrolment exceeds 39,000 students, and its alumni, faculty, and affiliates include 16 Nobel laureates and 3 prime ministers of Canada.

The university’s medical roots run deep: its Faculty of Medicine traces back to the Montreal Medical Institution, founded in 1823, which became Canada’s first medical school when it joined McGill College in 1829.

Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.

More on this story: GLP-1 Users May Regain 75% of Lost Weight After Stopping Medication · Out-of-Pocket Costs Rival Vomiting in GLP-1 Discontinuation

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Keep reading

  • Heartburn vs. Heart Attack: Key Symptom Differences, Risk Factors, and When to Call 911
  • Brazil SUS to Start Bowel Câncer Screening at 50 in December; Age Cutoff Based on Resources, Not Risk
  • GIBS Closes Inquiry into Ex-Detective Rudolf Flaška Death (archyde.com)

Related

Search:

World Today News

World Today News is your trusted source for global journalism — breaking headlines, in-depth analysis, and reporting from around the world.

Quick Links

  • Privacy Policy
  • About Us
  • Accessibility statement
  • California Privacy Notice (CCPA/CPRA)
  • Contact
  • Cookie Policy
  • Disclaimer
  • DMCA Policy
  • Do not sell my info
  • EDITORIAL TEAM
  • Terms & Conditions

Browse by Location

  • GB
  • NZ
  • US

Connect With Us

© 2026 World Today News. All rights reserved. Your trusted global news source directory.
For contact, advertising, copyright, issues email: [email protected]

Privacy Policy Terms of Service